https://www.youtube.com/watch?v=kq8HedjNQGA&t=16m40s

Highly accomplished Pediatric Oncologist from St. Jude Children’s Research Hospital and CMO for Novocure Brings Great Promise for People with Challenging Conditions

Company’s Phase 2 clinical trial aims to find meaningful clinical endpoints regarding tumor regression and survival rates.

Fast Company has listed SonALAsense as an honorable mention in the health category of their annual ‘World Changing Ideas Awards’.

Multisite study will test sonodynamic therapy in pediatric patients with diffuse intrinsic pontine glioma (DIPG).

April recently joined SonALAsense as Director of Patient Advocacy and Engagement, helping build alliances with patient and trade organizations / associations to raise awareness of, and educate on, sonodynamic therapy and recruit patients for recurrent glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG) clinical trials.

Company has received Safe to Proceed letters from FDA for two clinical trials in life-threatening brain tumors, DIPG trial is open and actively recruiting, it has expanded its executive leadership team and scientific advisory board and completed a Series B funding round.

Dr. Scott Plotkin, MD, PhD is the Executive Director at the Pappas Center for Neuro-Oncology at Massachusetts General Hospital and the Giovanni Armenise– Harvard Professor of Neurology at Harvard Medical School. He completed his neurology training at Mass General Brigham and Women's Hospital in Boston in 2002, and then trained in neuro-oncology at Mass General Hospital the following year. He has been on the faculty ever since and now also sits on the Scientific Advisory Board for SonALAsense.

Dr. Stuart Marcus has devoted most of his life to eradicating cancer after experiencing the horrors of the disease taking his beloved grandmother as a child in the ‘50s when few good options for treatment were available.

Trial provides proof of concept for this new metabolically targeted, rapidly acting technology platform for brain tumors and other lethal cancers

Professor Mitchel S. Berger, MD, Director of the UCSF Brain Tumor Center

Study combines metabolic targeting of glioblastoma with inert drug activated using MR-guided focused ultrasound